药康生物(688046) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥158,699,942.93, representing a year-on-year increase of 16.76%[5] - The net profit attributable to shareholders for Q3 2023 was ¥40,145,535.94, a decrease of 13.65% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥32,130,376.35, an increase of 38.60% year-on-year[5] - The net profit attributable to shareholders for the year-to-date period was ¥117,714,006.94, down 8.13% year-on-year due to reduced government subsidies[11] - Net profit for the third quarter of 2023 was ¥117,714,006.94, a decrease of 8.8% from ¥128,126,125.21 in the same quarter of 2022[24] - Earnings per share for the third quarter of 2023 were ¥0.29, down from ¥0.33 in the same quarter of 2022[25] Assets and Liabilities - The total assets at the end of Q3 2023 reached ¥2,478,090,797.03, reflecting a growth of 9.96% compared to the end of the previous year[6] - Total liabilities as of the end of the third quarter of 2023 amounted to ¥395,198,188.39, compared to ¥276,002,396.33 at the end of the same period in 2022, reflecting a 43.2% increase[21] - Total equity attributable to shareholders reached ¥2,082,892,608.63, an increase of 5.3% from ¥1,977,692,216.51 in the previous year[21] - The company has a total of 850,815,221.40 in non-current assets, an increase from ¥786,684,482.63 year-over-year[19] Cash Flow - The company reported a cash flow from operating activities of ¥37,151,483.21 for the year-to-date period, a decrease of 20.95%[6] - Cash inflow from operating activities for the first three quarters of 2023 was $411,249,887.13, an increase of 7.5% compared to $383,772,465.18 in the same period of 2022[28] - Net cash flow from operating activities decreased to $37,151,483.21 in 2023 from $46,996,531.16 in 2022, representing a decline of 21.5%[28] - Total cash inflow from investment activities surged to $1,752,309,699.74 in 2023, compared to $487,958,702.09 in 2022, marking a significant increase of 259.5%[29] - Net cash flow from investment activities improved to $157,192,101.42 in 2023, a recovery from a negative cash flow of $990,833,403.54 in 2022[29] - Cash inflow from financing activities totaled $86,000,000.00 in 2023, a decrease from $1,030,507,123.44 in 2022[29] - Net cash flow from financing activities was $43,951,472.00 in 2023, down from $1,003,367,249.60 in 2022, indicating a decline of 95.6%[29] - The net increase in cash and cash equivalents for the period was $240,089,731.99, compared to $62,239,606.37 in 2022, reflecting a growth of 285.5%[29] - The ending balance of cash and cash equivalents reached $661,682,486.12 in 2023, up from $355,757,001.38 in 2022, an increase of 86.0%[29] Research and Development - Research and development expenses for Q3 2023 amounted to ¥24,847,611.77, an increase of 8.40% year-on-year, accounting for 15.66% of operating revenue[6] - The company is focusing on large-scale R&D projects such as "antibody humanization" and "real-world animal models," contributing to increased R&D expenses[11] - Research and development expenses for the first three quarters of 2023 were ¥75,305,788.45, up 22.4% from ¥61,531,906.43 in the same period of 2022[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,437[13] - The largest shareholder, Nanjing Laoyan Venture Capital Partnership, holds 201,817,185 shares, accounting for 49.22% of total shares[14] - The top ten shareholders include several state-owned and private investment firms, indicating a diverse ownership structure[16] Other Financial Metrics - The basic earnings per share for Q3 2023 were ¥0.10, down 9.09% from the previous year[6] - The weighted average return on equity decreased to 1.95%, a drop of 0.48 percentage points compared to the previous year[6] - The company reported accounts receivable of ¥281,444,035.75, compared to ¥185,215,501.12 in the previous year[19] - The company has shown a significant increase in contract liabilities, which rose to ¥98,506,720.56 from ¥89,153,329.74, reflecting a growth of 15.1%[21] - The company reported a financial expense of -¥11,168,599.29 for the first three quarters, compared to -¥11,843,910.91 in the previous year[23] - The cash flow statement for the first three quarters of 2023 is currently unaudited, indicating ongoing financial assessments[27]